Cytokinetics

Polaris Capital Management added Cytokinetics to its Q2 2026 Global Equity Strategy, citing FDA approval of Myqorzo for hypertrophic cardiomyopathy and its perceived superiority to Bristol Myers Squibb's Camzyos in symptom relief and dosing simplicity. Cytokinetics closed at $67.59 on Sept. 22, 2026, with a market cap of $9.4 billion, a 52-week range of $47.22–$88.31 and a one-month decline of 14.66% versus a 52-week gain of 39.97%. Polaris noted the company amid strong quarter-wide gains driven by AI holdings, and hedge fund ownership of Cytokinetics rose to 78 portfolios at quarter end. » Mere på finance.yahoo.com

At the Citigroup conference, Cytokinetics reported a better-than-expected launch for MYQORZO in obstructive HCM, capturing a 40% share of new prescriptions by the end of Q2 2026. ACACIA-HCM phase 3 data showed superiority in non-obstructive HCM (NHCM) and support a planned regulatory filing; the company estimates NHCM could represent about 50% of the HCM market. There was a slight imbalance of serious heart-failure events in ACACIA, which the company views as manageable and plans to publish additional safety data. Cytokinetics plans to increase SG&A spending to support NHCM expansion and its European roll‑out (Germany launched, UK Q4 2026, other markets in 2027) and is advancing the COMET-HF confirmatory study of Omecamtiv Mecarbil in parallel. » Mere på de.investing.com

Cytokinetics reported a loss of $1.50 per share for Q2 2026 on revenue of $28.6 million, well above the consensus estimate of $17.09 million. The driver was the launch of the heart drug MYQORZO, which generated net product revenues of $25.3 million and treated more than 1,500 patients by the end of the quarter. The company raised its 2026 spending expectations due to increased commercial investments and holds $1.7 billion in cash. Management emphasized continued market momentum but noted risks from high costs, reliance on MYQORZO and reimbursement uncertainties. » Mere på de.investing.com

The MHRA has approved Cytokinetics’ Aficamten (MYQORZO) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients. NICE recommends use in England and Wales for patients in NYHA classes II–III as an add‑on to optimized standard therapy or as monotherapy when there are contraindications. The decision is based on the phase‑3 SEQUOIA‑HCM study, which showed a mean difference in peak oxygen uptake of 1.7 ml/kg/min (p < 0.001) versus placebo. Common adverse events included hypertension, palpitations, dizziness and systolic dysfunction; availability through the NHS is expected later this year. » Mere på de.investing.com

Cytokinetics is transitioning from development to commercial stage following regulatory approvals for Myqorzo in the US, Europe and China, with early physician adoption and patient response supporting initial sales momentum. Positive trial readouts are expanding the drug's potential into related cardiac indications, while a differentiated mechanism and a pipeline of next-generation candidates could broaden its addressable market. Market interest and volume-supported price action indicate accumulation as investors reassess long-term growth and pricing power in a market with limited competition. » Mere på finance.yahoo.com